Daniel R Mangels1, Ashwin Nathan1, Sony Tuteja1, Jay Giri1, Taisei Kobayashi2. 1. Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. 2. Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. Taisei.Kobayashi@uphs.upenn.edu.
Abstract
PURPOSE OF REVIEW: Antiplatelet therapies are pivotal treatments in the management of acute coronary syndrome (ACS) with or without revascularization. In recent years, the use of P2Y12 antagonists prior to catheterization, so-called pretreatment, has been questioned, particularly in patients who may be at higher bleeding risks. The purpose of this review was to evaluate the current literature on contemporary and novel antiplatelet therapy in the pretreatment and treatment of ACS. RECENT FINDINGS: The P2Y12 receptor antagonists are associated with substantial reductions in morbidity and mortality for all types of ACS but only clopidogrel and ticagrelor have sufficient evidence for use in the pretreatment setting. The data regarding prasugrel support the use in patients undergoing percutaneous intervention (PCI). The glycoprotein IIa/IIIb antagonists are the most optimal for use in high-risk ACS as an adjuvant therapy during and after PCI. In summary, although all P2Y12 antagonists have morbidity- and mortality-reducing effects in ACS, only clopidogrel and ticagrelor have sufficient evidence in the pretreatment setting. Newer antiplatelet therapies, most notably the protease-activated receptor 1 antagonists, are evolving and promising but are associated with greater bleeding risks.
PURPOSE OF REVIEW: Antiplatelet therapies are pivotal treatments in the management of acute coronary syndrome (ACS) with or without revascularization. In recent years, the use of P2Y12 antagonists prior to catheterization, so-called pretreatment, has been questioned, particularly in patients who may be at higher bleeding risks. The purpose of this review was to evaluate the current literature on contemporary and novel antiplatelet therapy in the pretreatment and treatment of ACS. RECENT FINDINGS: The P2Y12 receptor antagonists are associated with substantial reductions in morbidity and mortality for all types of ACS but only clopidogrel and ticagrelor have sufficient evidence for use in the pretreatment setting. The data regarding prasugrel support the use in patients undergoing percutaneous intervention (PCI). The glycoprotein IIa/IIIb antagonists are the most optimal for use in high-risk ACS as an adjuvant therapy during and after PCI. In summary, although all P2Y12 antagonists have morbidity- and mortality-reducing effects in ACS, only clopidogrel and ticagrelor have sufficient evidence in the pretreatment setting. Newer antiplatelet therapies, most notably the protease-activated receptor 1 antagonists, are evolving and promising but are associated with greater bleeding risks.
Authors: Gilles Montalescot; Leonardo Bolognese; Dariusz Dudek; Patrick Goldstein; Christian Hamm; Jean-Francois Tanguay; Jurrien M ten Berg; Debra L Miller; Timothy M Costigan; Jochen Goedicke; Johanne Silvain; Paolo Angioli; Jacek Legutko; Margit Niethammer; Zuzana Motovska; Joseph A Jakubowski; Guillaume Cayla; Luigi Oltrona Visconti; Eric Vicaut; Petr Widimsky Journal: N Engl J Med Date: 2013-09-01 Impact factor: 91.245
Authors: N S Kleiman; A M Lincoff; G C Flaker; K S Pieper; R G Wilcox; L G Berdan; T J Lorenz; D V Cokkinos; M L Simoons; E Boersma; E J Topol; R M Califf; R A Harrington Journal: Circulation Date: 2000-02-22 Impact factor: 29.690
Authors: Dominick J Angiolillo; Fabiana Rollini; Robert F Storey; Deepak L Bhatt; Stefan James; David J Schneider; Dirk Sibbing; Derek Y F So; Dietmar Trenk; Dimitrios Alexopoulos; Paul A Gurbel; Willibald Hochholzer; Leonardo De Luca; Laurent Bonello; Daniel Aradi; Thomas Cuisset; Udaya S Tantry; Tracy Y Wang; Marco Valgimigli; Ron Waksman; Roxana Mehran; Gilles Montalescot; Francesco Franchi; Matthew J Price Journal: Circulation Date: 2017-10-30 Impact factor: 29.690
Authors: Paul A Gurbel; Kevin P Bliden; Kathleen Butler; Mark J Antonino; Cheryl Wei; Renli Teng; Lars Rasmussen; Robert F Storey; Tonny Nielsen; John W Eikelboom; Georges Sabe-Affaki; Steen Husted; Dean J Kereiakes; David Henderson; Dharmendra V Patel; Udaya S Tantry Journal: Circulation Date: 2010-03-01 Impact factor: 29.690
Authors: Gregg W Stone; Michel E Bertrand; Jeffrey W Moses; E Magnus Ohman; A Michael Lincoff; James H Ware; Stuart J Pocock; Brent T McLaurin; David A Cox; M Zubair Jafar; Harish Chandna; Franz Hartmann; Franz Leisch; Ruth H Strasser; Martin Desaga; Thomas D Stuckey; Richard B Zelman; Ira H Lieber; David J Cohen; Roxana Mehran; Harvey D White Journal: JAMA Date: 2007-02-14 Impact factor: 56.272
Authors: Robert A Harrington; Gregg W Stone; Steven McNulty; Harvey D White; A Michael Lincoff; C Michael Gibson; Charles V Pollack; Gilles Montalescot; Kenneth W Mahaffey; Neal S Kleiman; Shaun G Goodman; Maged Amine; Dominick J Angiolillo; Richard C Becker; Derek P Chew; William J French; Franz Leisch; Keyur H Parikh; Simona Skerjanec; Deepak L Bhatt Journal: N Engl J Med Date: 2009-12-10 Impact factor: 91.245
Authors: Argentina Ornelas; Niki Zacharias-Millward; David G Menter; Jennifer S Davis; Lenard Lichtenberger; David Hawke; Ernest Hawk; Eduardo Vilar; Pratip Bhattacharya; Steven Millward Journal: Cancer Metastasis Rev Date: 2017-06 Impact factor: 9.264